Mammalian Cell Culture Perfusion Patents: Leaders & Trends 2026
- 25.5% concentration at the top. The five leading assignees hold 560 of 2,197 records in scope, but the remaining ranked leaders thin out fast — a long tail dominates by count of entrants.
- Filings cooled from a 2020 peak. Volume peaked at 83 in 2020; the last complete comparison shows 2021's 36 filings falling to 25 by 2024, a 31% decline, though 2025-26 figures are still filling in under the usual publication lag.
- Bioreactor apparatus claims trail bioprocess claims. C12M (bioreactors & enzyme apparatus) sits at 32.0% of records versus C12N (microorganisms & genetic engineering) at 84.3% — a gap that points to under-claimed hardware and control-loop space.
Filing growth compares 2021 (36 records) with 2024 (25) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,197 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape maps 2,197 published records at the intersection of mammalian, animal or CHO cell culture and the operating parameters that define perfusion mode: perfusion rate, bleed control, residence time, nutrient renewal, waste removal and steady-state operation. The scope is filtered to C12N5/00, C12M3/00 and C12Q1/02, so it captures both the biological engineering of the cell line and the apparatus and measurement layer that keeps a continuous culture in steady state.
Coverage runs from 2015 through the 2026-07-31 cut-off. Because publication lags filing by roughly 18 months, the most recent one to two years in any trend understate real filing activity and should be read as provisional rather than a signal of decline.
Filing trends and technology composition
Two views of the same 2,197-record corpus: the filing trend by publication year, and the IPC subclasses that describe what is actually being claimed.
Filing trend, 2017-2026
Filings rose to a peak of 83 in 2020, then eased — the last complete year-over-year comparison available shows 2021's 36 filings dropping to 25 by 2024, a 31% decline. Treat 2025 and 2026 as undercounted rather than as continued decline.
IPC subclass composition
C12N (microorganisms & genetic engineering) appears in 84.3% of the 2,197 records, far ahead of C07K (peptides & proteins) at 35.5% and C12M (bioreactors & enzyme apparatus) at 32.0%. Because records carry multiple classes, these shares sum past 100% and should be read individually, not summed.
Shares are the percentage of the 2,197 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Mammalian Cell Culture Perfusion Culture with Eureka
This page is one run against one query. Ask Eureka your own question about mammalian cell culture perfusion culture and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art and the newest representative filing
US12227571B2 — Continuous manufacturing process for bispecific antibody products
Filed by Amgen and granted 2025-02-18, this patent covers a continuous upstream process for producing bispecific antibody products in a perfusion bioreactor: growing a mammalian cell culture at a first perfusion rate until a target viable cell density is reached, then holding a second perfusion rate while keeping the bispecific antibody concentration in the bioreactor below a set threshold, before downstream processing.Abstract condensed from the original filing for length.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6100061A | Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recoverin… | 302 |
| 2 | US5985653A | Incubator apparatus for use in a system for maintaining and growing biological cells | 297 |
| 3 | US6228635B1 | Portable cell growth cassette for use in maintaining and growing biological cells | 284 |
| 4 | US6238908B1 | Apparatus and method for maintaining and growth biological cells | 273 |
| 5 | US20050124010A1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and opt… | 268 |
| 6 | US5976833A | Method for animal cell culture | 265 |
| 7 | US5888807A | Devices for maintaining and growing human stem and/or hematopoietics cells | 235 |
| 8 | US5763266A | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells | 213 |
| 9 | US5686304A | Cell culture apparatus and method | 211 |
| 10 | US5356804A | Cloning and expression of biologically active human alpha -galactosidase A | 204 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus — read them as a measure of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-throughs on concentration, technology mix and receiving-office choice that matter more than the raw record count.
Concentrated at the top, thin after that
The leading assignee holds 262 records against a fifth-place figure of 66 and a tenth-place figure of 41 — a steep drop-off. Combined, the top ten hold 36.4% of all records in scope, meaning the other 90 ranked leaders and the unranked tail account for the majority of filings individually in small numbers.
Biological claims outweigh apparatus claims
C12N (microorganisms & genetic engineering) touches 84.3% of records while C12M (bioreactors & enzyme apparatus) touches only 32.0%. That gap suggests the hardware, sensor and control-loop layer that actually runs a perfusion process is comparatively less claimed than the cell-line and expression biology sitting inside it.
US and EPO dominate, PCT signals global intent
The United States leads with 509 filings, Europe follows with 392, and 254 records route through WIPO's PCT system, indicating a meaningful share of applicants are still deciding on jurisdiction. Canada, Australia and Israel each carry over 160 records, showing this is not a US-only prosecution story.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to mammalian cell culture perfusion culture, with the prior art for and against each one.
Who is filing, and where the gaps sit
The assignee ranking runs 100 companies deep, counted in records, with a small group at the top and a long tail of single- and double-digit filers behind them.
A clear leader, then a steep drop
The top-ranked assignee holds 262 records, more than four times the fifth-place figure of 66, and more than six times tenth place at 41. Co-assignee activity is concentrated too: the strongest pairing recurs at 75 shared records, well above the next pairings at 14 each, pointing to a small cluster of corporate affiliates filing jointly.
Latest-year momentum is flat across the tracked leaders
Several of the assignees tracked for year-over-year momentum, including the top-ranked filer, show zero records in the latest year, consistent with the broader publication lag rather than a genuine stop in filing. Treat any single-year momentum figure for 2025-26 as provisional.
The tail outnumbers the top ten by volume
With the top ten assignees holding 36.4% of all 2,197 records, the remaining 63.6% is spread across the other ranked entrants and unranked filers. That distribution favours a freedom-to-operate search over any single-competitor watch, since no one player controls the field outright.
| Assignee | Recent year | YoY |
|---|---|---|
| Amgen Inc. | 0 | -100% |
| Merck Patent GmbH | 0 | — |
| Baxalta Inc. | 0 | — |
| Baxalta GmbH | 0 | — |
| Ares Trading SA | 0 | — |
| Boehringer Ingelheim International GmbH | 0 | — |
| Takeda Pharmaceutical Company Limited | 0 | — |
| University of California | 0 | — |
Where to take this from here
The landscape points to specific next steps depending on whether the goal is freedom-to-operate, competitive tracking or white-space filing.
Run a freedom-to-operate check on apparatus claims
With C12M apparatus claims at only 32.0% of records against 84.3% for the core biology, a targeted search on bioreactor and control-loop claims is likely to surface less-crowded prior art than a search on cell-line biology alone.
Explore the apparatus subset in EurekaTrack the leading assignees' co-filing patterns
The strongest co-assignee pairing recurs at 75 shared records, suggesting corporate affiliate structures worth watching for consolidated filing strategy rather than treating each entity separately.
Map assignee relationships in EurekaRevisit 2025-26 filings once the publication lag clears
The apparent cooling after the 2020 peak is measured only through 2024; the 2025-26 figures will keep rising as later publications catch up, so any conclusion about a continuing slowdown should wait for that data to settle.
Set a filing-trend alert in EurekaCommon questions on this landscape
It is moderately concentrated at the very top and long-tailed after that. The five leading assignees hold 560 of 2,197 records in scope, or 25.5%, and the top ten hold 36.4% combined. Beyond the leader, which sits at 262 records, the drop to fifth place (66) and tenth place (41) is steep, meaning the ranked leaders past the top few file in much smaller, more comparable numbers, and the remaining majority of the field is spread across a long tail of smaller filers.
Publication lags filing by roughly 18 months, so any patent filed in 2025 or 2026 typically has not published yet and will not show up in a count taken today. The dataset's peak year is 2020 at 83 filings, and the last year-over-year comparison that can be treated as complete runs from 2021 (36) to 2024 (25), a 31% decline. Figures for 2025 and 2026 are still filling in and should not be read as evidence the technology is falling out of favor.
The apparatus and monitoring layer looks comparatively open relative to the underlying biology. C12N, covering microorganisms and genetic engineering, appears in 84.3% of the 2,197 records, while C12M, covering bioreactors and enzyme apparatus, appears in only 32.0%. That gap suggests specific sub-areas such as bleed-rate control algorithms, single-use perfusion sensors and real-time residence-time monitoring carry comparatively less claim density than the expression and cell-line biology around them.
US12227571B2, assigned to Amgen and granted in February 2025, claims a continuous upstream manufacturing process for bispecific antibody products made in a perfusion bioreactor. The process runs a mammalian cell culture at a first perfusion rate until a target viable cell density is reached, then switches to a second perfusion rate while keeping the bispecific antibody concentration below a defined threshold, ahead of downstream purification. It is a process claim tied specifically to bispecific antibody products and a two-stage perfusion-rate schedule, not a claim over perfusion culture generally, so work outside that specific rate-switching and product-concentration control scheme sits outside its scope.
The United States leads with 509 filings in this dataset, followed by Europe (EPO) at 392 and the WIPO PCT route at 254, with Australia, Israel and Canada each above 160. The strong PCT figure indicates many applicants are filing internationally before committing to specific national or regional phases, so a competitive watch limited to the US or Europe alone would miss a meaningful share of activity, particularly in Australia and Israel where filing counts are still substantial.
Research Mammalian Cell Culture Perfusion Culture in depth with Eureka
Go past this page: query the whole mammalian cell culture perfusion culture corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.